Description
(AWP Alliance News) - Roche today launched its VENTANA BAP1 (SP527) test globally, expanding its cancer diagnostics portfolio. The test helps distinguish malignant mesothelioma from other cancers and benign tissue growth. Used alongside recently launched diagnostic tests, it can reduce tissue loss during diagnosis, preserving samples for molecular sequencing and precision medicine testing. The launch targets a disease often diagnosed late, with median overall survival of just 12 to 18 months.
https://www.globenewswire.com/NewsRoom/ReleaseNg/402533999
Disclaimer: This news brief was created using generative artificial intelligence. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire on October 28, 2026, and is solely responsible for the information contained therein.
